The medical equipment maker is set to pay as much as $925m to buy its portfolio company that will enable Novo, Merck & Co and Samsung to exit.
Medical device manufacturer Boston Scientific yesterday agreed to acquire its portfolio company Preventice Solutions, a US-based mobile healthcare technology developer backed by fellow corporates Novo, Merck & Co and Samsung.
The transaction is set to close by mid-2021 and will include a $925m upfront cash payment and an additional commercial milestone payment of up to $300m. Boston Scientific currently owns a roughly 22% stake in the company.
Founded in 2014, Preventice provides digital products for patients to communicate remotely with…
